Skip to main content

Centogene N.V. (CNTG)

NASDAQ: CNTG · IEX Real-Time Price · USD
10.09 -0.20 (-1.94%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap226.47M
Revenue (ttm)156.56M
Net Income (ttm)-26.20M
Shares Out22.45M
EPS (ttm)-0.82
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume20,908
Open10.19
Previous Close10.29
Day's Range9.93 - 10.30
52-Week Range8.61 - 14.79
Betan/a
AnalystsStrong Buy
Price Target20.84 (+106.5%)
Est. Earnings DateDec 9, 2021

About CNTG

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including tar...

IndustryBiotechnology
IPO DateNov 7, 2019
Employees660
Stock ExchangeNASDAQ
Ticker SymbolCNTG
Full Company Profile

Financial Performance

In 2020, Centogene's revenue was 128.38 million, an increase of 163.18% compared to the previous year's 48.78 million. Losses were -21.49 million, 4.01% more than in 2019.

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 4 analysts, the average rating for Centogene stock is "Strong Buy." The 12-month stock price forecast is 20.84, which is an increase of 106.50% from the latest price.

Price Target
$20.84
(106.50% upside)
Analyst Consensus: Strong Buy

News

New Strong Sell Stocks for September 10th

CNTG, JOAN, STRT, ZNGA, and PTVE have been added to the Zacks Rank #5 (Strong Sell) List on September 10, 2021

Other symbols:JOANPTVESTRTZNGA
1 week ago - Zacks Investment Research

Centogene N.V. (CNTG) Reports Q2 Loss, Tops Revenue Estimates

Centogene N.V. (CNTG) delivered earnings and revenue surprises of -73.08% and 62.19%, respectively, for the quarter ended June 2021.

1 week ago - Zacks Investment Research

CENTOGENE Reports Second Quarter 2021 Financial Results

Strong Revenues and Steady Return to Core Business Growth; Surpasses Milestone of 200 Scientific Publications, Highlighting Value of Bio/Databank Strong Revenues and Steady Return to Core Business Growt...

1 week ago - GlobeNewsWire

CENTOGENE to Announce Second Quarter 2021 Financial Results on September 7, 2021

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, und...

2 weeks ago - GlobeNewsWire

CENTOGENE Appoints Patrice P. Denèfle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare D...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, unde...

1 month ago - GlobeNewsWire

CENTOGENE Announces Shareholders Approve All Resolutions at Annual General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 25, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, unde...

2 months ago - GlobeNewsWire

CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years

Highlights strategic priorities to lead data-driven insights creation for rare diseases at its Virtual Investor Event Highlights strategic priorities to lead data-driven insights creation for rare disea...

2 months ago - GlobeNewsWire

CENTOGENE Reports First Quarter 2021 Financial Results in the Lead Up to Virtual Investor Event

Further signs of recovery in the core rare disease business Further signs of recovery in the core rare disease business

3 months ago - GlobeNewsWire

Centogene N.V. (CNTG) Stock Jumps 7.5%: Will It Continue to Soar?

Centogene N.V. (CNTG) saw its shares surge in the last session with trading volume being higher than average.

3 months ago - Zacks Investment Research

CENTOGENE to Announce Q1 2021 Financial Results on June 16, 2021

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 09, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, unde...

3 months ago - GlobeNewsWire

CENTOGENE Announces Virtual Investor Event

New leadership team to present vision, strategy, and execution roadmap New leadership team to present vision, strategy, and execution roadmap

3 months ago - GlobeNewsWire

3 Medical Info System Stocks to Bank on Despite Decline in COVID-19 Cases

3 Medical Info System Stocks to Bank on Despite Decline in COVID-19 Cases

Other symbols:CERNCPSIDGX
3 months ago - Zacks Investment Research

CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia

Observational Study to Advance Genetic Understanding of FTD Being Conducted With Support From Alector Observational Study to Advance Genetic Understanding of FTD Being Conducted With Support From Alector

3 months ago - GlobeNewsWire

CENTOGENE Launches NEW CentoXome® - An Enhanced Whole Exome Sequencing Solution

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 01, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, unde...

3 months ago - GlobeNewsWire

CENTOGENE Announces the Nomination of Rene Just as Chief Financial Officer

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 26, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, under...

3 months ago - GlobeNewsWire

CENTOGENE Appoints Michael Motz as Chief Commercial Officer, Pharmaceuticals

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical ...

4 months ago - GlobeNewsWire

CENTOGENE Extends Global Parkinson's Disease Study

Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson's disease (PD)

4 months ago - GlobeNewsWire

Centogene (CNTG) Enters Oversold Territory

Centogene (CNTG) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

4 months ago - Zacks Investment Research

New CentoMD® 6.0 Update Brings Deeper Insights Into Rare Diseases

CENTOGENE's rare disease mutation database offers new features and previously unpublished variants CENTOGENE's rare disease mutation database offers new features and previously unpublished variants

4 months ago - GlobeNewsWire

CENTOGENE Discovers Six New Rare Diseases by Leveraging the Strength of Its Bio/Databank

Research leads to diagnosis and treatment options for rare disease patients Research leads to diagnosis and treatment options for rare disease patients

4 months ago - GlobeNewsWire

4 Medical Products Stocks Set to Beat This Earnings Season

Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.

Other symbols:BSXHOLXINGNLHOMIXRAY
4 months ago - Zacks Investment Research

CENTOGENE Reports Record Fourth Quarter and Full Year 2020 Financial Results

Delivers very strong financial results in unprecedented year Delivers very strong financial results in unprecedented year

5 months ago - GlobeNewsWire

CENTOGENE Extends Partnership With Takeda

CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 14, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical a...

5 months ago - GlobeNewsWire

CENTOGENE to Announce Full Year 2020 Financial Results on April 15, 2021

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 08, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinic...

5 months ago - GlobeNewsWire

CENTOGENE Reaches 10,000 Participant Milestone in Global Parkinson's Disease Study

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinica...

6 months ago - GlobeNewsWire